Francine Gervais
Corporate Officer/Principal at McGill University
Profile
Francine Gervais is a Professor at McGill University.
She was previously a Vice President-Research & Development at BELLUS Health, Inc. and a SVP & Vice President-Pharmaceutical Development at PainCeptor Pharma Corp.
She holds a doctorate degree from the University of Montréal.
Francine Gervais active positions
Companies | Position | Start |
---|---|---|
McGill University | Corporate Officer/Principal | - |
Former positions of Francine Gervais
Companies | Position | End |
---|---|---|
BELLUS HEALTH | Chief Tech/Sci/R&D Officer | - |
PainCeptor Pharma Corp.
PainCeptor Pharma Corp. Pharmaceuticals: MajorHealth Technology PainCeptor Pharma Corp. operates as a biopharmaceutical company which engages in the development of pharmaceuticals for chronic and acute pain. It offers next generation therapeutic drugs for the treatment of chronic and acute pain. The firms products includes NGF/p75-TrkA, ASIC1a and ASIC3. The company was founded by Louis Lamontagne in 2003 and is headquartered in St-Laurent, Canada. | Corporate Officer/Principal | - |
Training of Francine Gervais
University of Montréal | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 2 |
---|---|
PainCeptor Pharma Corp.
PainCeptor Pharma Corp. Pharmaceuticals: MajorHealth Technology PainCeptor Pharma Corp. operates as a biopharmaceutical company which engages in the development of pharmaceuticals for chronic and acute pain. It offers next generation therapeutic drugs for the treatment of chronic and acute pain. The firms products includes NGF/p75-TrkA, ASIC1a and ASIC3. The company was founded by Louis Lamontagne in 2003 and is headquartered in St-Laurent, Canada. | Health Technology |
BELLUS Health, Inc.
BELLUS Health, Inc. Pharmaceuticals: MajorHealth Technology BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. Its product BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada. | Health Technology |
- Stock Market
- Insiders
- Francine Gervais